• Satellos Bioscience published an investor presentation outlining its muscle-regeneration strategy for Duchenne muscular dystrophy built around forazapadin (SAT-3247).
• Program positioned as an oral, once-daily small molecule designed to restore muscle stem cell polarity via AAK1 inhibition.
• Clinical pipeline highlights two Phase 2 studies: BASECAMP in children ages 7-9 (N=51, placebo-controlled) and TRAILHEAD in adults ≥16 (open-label).
• Phase 1b in five adults cited 2x grip-strength increases, a 5.8% rise in predicted FVC, and biomarker shifts within 15 days.
• Shares trade as TSX: MSCL, NASDAQ: MSLE.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief on September 10, 2026, and is solely responsible for the information contained therein.